{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T10:40:04Z","timestamp":1781865604676,"version":"3.54.5"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T00:00:00Z","timestamp":1669161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In Europe, meningococcal (Men) vaccines are available against 5 of the 6 serogroups responsible of nearly all cases of invasive meningococcal disease (IMD). Meningococcal vaccination has been introduced in the national immunization programs (NIPs) for children and adolescents of numerous European countries, but with no consistent strategy across countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe IMD epidemiology, NIPs, and vaccination coverage rates (VCRs) in children and adolescents in 8 Western European countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Epidemiological data (from 1999 to 2019), NIPs regarding meningococcal vaccination status, and VCRs were collected from the European Centre for Disease Prevention and Control (ECDC) and\/or national websites.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MenB was the most common serogroup. In Belgium, Spain, France, the Netherlands, the United Kingdom (UK), and Portugal, incidence was greater for MenW than MenC. In 2019, MenB risk was covered in 2 countries (Italy, UK). MenC risk was covered in all countries, <jats:italic>via<\/jats:italic> MenC only (countries: <jats:italic>N\u2009<\/jats:italic>=\u20093), MenACWY only (<jats:italic>N\u2009<\/jats:italic>=\u20092), or MenC (infants\/children) and MenACWY (adolescents) (<jats:italic>N\u2009<\/jats:italic>=\u20093) vaccination. VCRs were higher in children than adolescents.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study confirmed the diversity of NIPs, including in neighboring European countries with similar factors like economic resources and epidemiological risk, thus indicating that other factors underlie NIPs. Convergence toward a more common immunization program including MenACWY and MenB vaccination would promote equity and safe travel regarding infectious diseases for young people, and possibly improve the understanding of vaccination by patients and healthcare professionals.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.1000657","type":"journal-article","created":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T07:17:20Z","timestamp":1669187840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8\u00a0Western European countries"],"prefix":"10.3389","volume":"10","author":[{"given":"Ga\u00eblle","family":"Pinto Cardoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Lagr\u00e9e-Chastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Caseris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Gaudelus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bakhache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Aliette","family":"Dommergues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Pauquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Pinquier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,23]]},"reference":[{"key":"B1","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martinon-Torres","year":"2016","journal-title":"J Adolesc Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40121-021-00468-w","article-title":"Healthcare resource consumption and cost of invasive meningococcal disease in France: a study of the national health insurance database","volume":"10","author":"Weil-Olivier","year":"2021","journal-title":"Infect Dis Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"Pastore celentano L; ECDC network members for invasive meningococcal disease. The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004-2014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"B6","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","article-title":"The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination","volume":"81","author":"Parikh","year":"2020","journal-title":"J Infect"},{"key":"B8","year":""},{"key":"B9","doi-asserted-by":"publisher","first-page":"2002075","DOI":"10.2807\/1560-7917.ES.2022.27.3.2002075","article-title":"Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017","volume":"27","author":"Nuttens","year":"2022","journal-title":"Euro Surveill"},{"key":"B10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic trends, global shifts in meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect Dis Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1586\/14760584.2016.1130628","article-title":"Routinely vaccinating adolescents against meningococcus: targeting transmission & disease","volume":"15","author":"Vetter","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/20477724.2021.1972663","article-title":"Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations","volume":"116","author":"Martinon-Torres","year":"2022","journal-title":"Pathog Glob Health"},{"key":"B13","year":""},{"key":"B14","year":""},{"key":"B15","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B vaccine and meningococcal carriage in adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","year":""},{"key":"B19","year":""},{"key":"B20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1080\/21645515.2020.1729030","article-title":"Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries","volume":"16","author":"Taha","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"B21","year":""},{"key":"B22","year":""},{"key":"B23","year":""},{"key":"B24","year":""},{"key":"B25","year":"2022"},{"key":"B26","year":""},{"key":"B27","year":"2022"},{"key":"B28","year":""},{"key":"B29","year":""},{"key":"B30","year":""},{"key":"B31","year":""},{"key":"B32","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/s0264-410x(01)00299-7","article-title":"Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story","volume":"20","author":"Miller","year":"2001","journal-title":"Vaccine"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in The Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1471-2334-12-35","article-title":"Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from The Netherlands","volume":"12","author":"Kaaijk","year":"2012","journal-title":"BMC Infect Dis"},{"key":"B36","year":""},{"key":"B37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jinf.2017.02.011","article-title":"Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015","volume":"74","author":"Parent du Chatelet","year":"2017","journal-title":"J Infect"},{"key":"B38","year":""},{"key":"B39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","article-title":"Economic evaluation of meningococcal vaccines: considerations for the future","volume":"21","author":"Christensen","year":"2020","journal-title":"Eur J Health Econ"},{"key":"B40","year":""},{"key":"B41","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"B42","year":""},{"key":"B43","year":""},{"key":"B44","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.idnow.2021.05.001","article-title":"Why should the meningococcal B vaccine be recommended, and therefore reimbursed, for infants in France?","volume":"51","author":"Gras-Le Guen","year":"2021","journal-title":"Infect Dis Now"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","article-title":"Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France","volume":"34","author":"Lecocq","year":"2016","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1080\/21645515.2020.1849518","article-title":"Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database","volume":"17","author":"Taha","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1186\/s12889-020-09946-1","article-title":"Systematic literature review of the impact and effectiveness of monovalent meningococcal C conjugated vaccines when used in routine immunization programs","volume":"20","author":"Tin Tin Htar","year":"2020","journal-title":"BMC Public Health"},{"key":"B48","year":""},{"key":"B49","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1136\/adc.2009.178459","article-title":"Primary-secondary working group (PSWG) of European academy of paediatrics (EAP). paediatric primary care in Europe: variation between countries","volume":"95","author":"van Esso","year":"2010","journal-title":"Arch Dis Child"},{"key":"B50","article-title":"The organization and delivery of vaccination services in the European union. Prepared for the European commission","volume-title":"European Observatory on health systems and policies","author":"Rechel","year":"2018"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1080\/21645515.2017.1313940","article-title":"Meningococcal serogroup B vaccine: knowledge and acceptability among parents in Italy","volume":"13","author":"Morrone","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vaccine.2014.10.035","article-title":"Recommendations for strengthening NITAG policies in developed countries","volume":"33","author":"Ricciardi","year":"2015","journal-title":"Vaccine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jinf.2021.11.016","article-title":"Surveillance and control of meningococcal disease in the COVID-19 era: a global meningococcal initiative review","volume":"84","author":"Alderson","year":"2022","journal-title":"J Infect"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e00516","DOI":"10.1002\/hsr2.516","article-title":"Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: a systematic review","volume":"5","author":"SeyedAlinaghi","year":"2022","journal-title":"Health Sci Rep"},{"key":"B55","author":"Clark","year":""}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1000657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T07:17:22Z","timestamp":1669187842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.1000657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,23]]},"references-count":55,"alternative-id":["10.3389\/fped.2022.1000657"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.1000657","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,23]]},"article-number":"1000657"}}